Medexus Pharmaceuticals (MDP) investor relations material

Executive summary

• Strong first quarter results driven by GRAFAPEX, which delivered its best quarter to date and is a key growth driver, with record product-level performance and strong commercial traction.

• GRAFAPEX net revenue reached $4.9 million, with broad adoption and repeat orders from healthcare institutions, and 118% year-over-year patient demand growth.

• Commercial adoption and payer coverage for GRAFAPEX remain highly encouraging, supporting long-term revenue targets.

• Strategic expansion in the Allo-HSCT space with exclusive Canadian rights to UM171 Cell Therapy, positioning the portfolio for long-term value creation.

Financial highlights

• Net revenue for fiscal Q1 2027 increased to $28.6 million, up 16.3% or $4.0 million year-over-year, mainly due to GRAFAPEX and IXINITY.

• Adjusted EBITDA rose to $4.7 million, a 38.2% increase year-over-year.

• Operating income improved to $2.1 million, up 133.3% from the prior year.

• Gross profit was $15.9 million, up from $13.8 million year-over-year; gross margin was 55.6%, slightly down due to prior year royalty revenue.

• Net income was $0.5 million, consistent with the prior year period.

Outlook and guidance

• GRAFAPEX expected to achieve $30–32 million in product-level net revenue for fiscal 2027.

• Five-year annual net revenue target for GRAFAPEX set at $100–175 million, representing 29%–42% market share.

• Continued investment in Allo-HSCT and adjacent areas, with UM171 Cell Therapy as a strategic focus; commercialization in Canada not expected before 2028 or possibly 2031.

• Expectation of meaningful operating cash flow generation as GRAFAPEX scales.